BHC
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +7.7% ·
share flow +4.8% ·
net new positions +7.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -5 | 75.64M | $382.99M | +3 | −7 |
| Q1 2026 | 85 | -6 | 79.75M | $438.97M | +2 | −9 |
| Q4 2025 | 92 | +1 | 89.74M | $627.51M | +2 | — |
| Q3 2025 | 19 | +1 | 25.30M | $166.30M | +2 | −2 |
| Q2 2025 | 16 | -1 | 54.52M | $364.89M | — | −1 |
| Q1 2025 | 15 | +1 | 47.24M | $307.27M | +2 | −1 |
| Q4 2024 | 14 | +1 | 50.10M | $405.72M | +1 | — |
| Q3 2024 | 13 | +1 | 47.82M | $391.50M | +2 | −1 |
| Q2 2024 | 12 | — | 55.66M | $388.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 34.72M | 0.0% | $279.85M | 3.8% | Held | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 5.20M | +1.1% | $41.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 5.20M | +1.1% | $41.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Arrowstreet Capital ✦ | 4.77M | +46.3% | $38.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Oaktree Capital Management ✦ | 1.27M | 0.0% | $10.24M | 0.2% | Held | 3 | SEC ↗ |
| 6 | GAMCO Investors ✦ | 1.08M | +1.2% | $8.67M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 715.57K | +12.5% | $7.63M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 715.57K | +12.5% | $7.63M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 544.71K | +84.1% | $4.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 544.71K | +84.1% | $4.39M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Bridgewater Associates ✦ | 501.91K | +113.7% | $4.05M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 495.17K | +1761.5% | $3.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Millennium Management ✦ | 443.36K | +10.3% | $3.57M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 265.46K | +688.2% | $2.14M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 66.15K | New | $533,185 | 0.0% | New | 1 | SEC ↗ |
| 16 | Norges Bank ✦ (passive) | 17.52K | -97.6% | $141,179 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Elliott Investment Management ✦ | 11.50K | 0.0% | $92,690 | 0.0% | Held | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Gotham Asset Management | $533,185 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 232.19M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 36.83K sh · $258,894
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology